Emerging Markets Earnings Roundup: Abbott, AbbVie, J&J, GSK (Part 3)
This article was originally published in PharmAsia News
After Abbott/AbbVie split, emerging markets represent 40% of Abbott’s sales compared to 15% of AbbVie sales. Abbott, J&J and GSK report dismal sales in Europe, noting that EMs remain a bright spot.
You may also be interested in...
Since its split from Abbott Laboratories in January, AbbVie has been telling a story of gradually overcoming loss of revenue due to generic-challenged lipid franchise via Humira growth and a promising pipeline. For the first quarter of 2013, Humira generated worldwide sales of $2.244 billion, slightly more than half of the company’s entire revenue base.
GlaxoSmithKline is bundling around 50 legacy drugs comprising some £3 billion ($4.6 billion) in annual sales into a standalone global portfolio, in a “housekeeping” move that Britain’s biggest medicines maker says is needed to better prepare the group for its coming wave of new product launches.
As “The Pink Sheet” team heads to BIO’s annual partnering convention in Chicago, the Russian government rejects Abbott’s bid for NGO Petrovax. Plus news on deals between Roche and Ascletis, Lilly and Siemens, and Santaris and Bristol-Myers.